Cytori Therapeutics Inc


Analysts Remain Buyers of 2 Volatile Healthcare Stocks: Cytori Therapeutics Inc (CYTX) and TearLab Corp (TEAR)

Cytori Therapeutics Inc: Should You Catch This Falling Knife? Cytori Therapeutics Inc (NASDAQ:CYTX) shares are crashing over 60% in Monday’s trading session, after the …

Why Cytori Therapeutics Inc (CYTX) Shares Collapsed Today

Monday turned out to be a nightmare for shareholders of Cytori Therapeutics Inc (NASDAQ:CYTX), after the drug maker announced disappointing top-line, preliminary data …

Cytori Therapeutics Inc (CYTX) Tumbles To 52-Week Low On Back Of Share Dilution

Cytori Therapeutics Inc (NASDAQ:CYTX) announced the pricing of its underwritten public offering of 8,600,000 of its common shares at a price to the public …

Maxim Analyst Comments on Cytori Therapeutics Inc Following Azaya Acquisition

Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Cytori Therapeutics Inc (NASDAQ:CYTX) with a price target of $6.00, after the drug …

Company Update (NASDAQ:CYTX): Cytori Therapeutics Inc Announces Two Year Follow-Up Published on EU Scleroderma Trial

Cytori Therapeutics Inc (NASDAQ:CYTX) announced publication of two-year clinical follow-up of patients treated with a single administration of ECCS-50 in the SCLERADEC-I pilot …

Stock Update (NASDAQ:CYTX): Cytori Therapeutics Inc Presents Compelling Cell Therapy Results at Annual International Federation of Adipose Therapeutics Conference

Cytori Therapeutics Inc (NASDAQ:CYTX) scientists presented two research papers at the annual meeting of the International Federation of Adipose Therapeutics and Science (iFATS) …

Company Update (NASDAQ:CYTX): Cytori Therapeutics Inc Strengthens Global Intellectual Property Portfolio with Key Patents

Cytori Therapeutics Inc (NASDAQ:CYTX) announced the issuance of a number of key patents that strengthen its intellectual property portfolio in the U.S.

Stock Update (NASDAQ:CYTX): Cytori Therapeutics Inc Granted FDA Orphan Drug Designation for ECCS-50 in Scleroderma

Cytori Therapeutics Inc (NASDAQ:CYTX) announced that the US FDA Office of Orphan Products Development (OOPD) has granted Cytori an orphan drug designation for …

Stock Update (NASDAQ:CYTX): Cytori Therapeutics Inc Announces Publication of Cytori Cell Therapy for Combined Radiation and Thermal Injury

Cytori Therapeutics Inc (NASDAQ:CYTX) announced the publication of preclinical safety and efficacy study data using Cytori Cell Therapy™ for combined radiation and thermal …

Stock Update (NASDAQ:CYTX): Cytori Therapeutics Inc Partner Kerastem Completes Enrollment of US Phase II Trial for Early Stage Hair Loss

Cytori Therapeutics Inc (NASDAQ:CYTX) announced that its licensee Kerastem Technologies, LLC, has completed enrollment of STYLE, a US phase II clinical trial investigating early stage …